



PHONE: 605-773-3495 | FAX: 605-773-5246

WEB: [DSS Medicaid Prior Authorizations](#) | EMAIL : DSSMedicaidpa@state.sd.us

ULTOMIRIS PRIOR AUTHORIZATION REQUEST FORM

Use this form when therapy is requested for neuromyelitis optica spectrum disorder (NMOSD)

This form **MUST BE** submitted with medical records to support services

Date:		
RECEIPIENT INFORMATION		
Medicaid ID:	Date of Birth:	Sex: M F
Last Name:	First Name:	
GENERAL INFORMATION		
First Date of Service:	Last Date of Service:	
Primary Diagnosis Code:	HCPC Code:	
Drug Name:	Quantity:	
Hospitalizations/Treatments/Medications Used in the last 6 months:		
POINT OF CONTACT		
Name and Title:		
Email:	Phone:	Fax:
<small><i>Note: The point of contact is the individual completing the PA and would be the contact for questions SD Medicaid may have regarding the PA. The determination notice will be sent to the listed point of contact.</i></small>		
REFERRING PROVIDER INFORMATION		
Name:		
NPI #:	Taxonomy:	
Phone:	Fax:	
SERVICING PROVIDER INFORMATION		
Name:		
Address:		
NPI #:	Taxonomy:	
Phone:	Fax:	

CRITERIA		
Medical records to support use of product are submitted		
Initial Therapy (check one)	Yes	No
	Therapy is requested by or in consultation with a neurologist	
	Individual is ≥18 years of age	
	Documentation is submitted indicating presence of seropositive aquaporin-4 (AQP4) antibodies	
	Individual has a documented diagnosis of NMOSD with at least one core clinical characteristic below: <ul style="list-style-type: none"> • Optic neuritis • Acute myelitis • Area postrema syndrome or episode of otherwise unexplained hiccups or nausea and vomiting • Acute brainstem syndrome • Symptomatic narcolepsy • Acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions • Symptomatic cerebral syndrome with NMOSD-typical brain lesions 	
	Documentation is provided indicating previous failure, contraindication or intolerance to at least two of the following (with at least one being a C5 complement inhibitor): <ul style="list-style-type: none"> • Rituximab • Tocilizumab • Inebilizumab (Uplizna) • Satralizumab-mwge (Enspryng) • Eculizumab (Soliris) 	
	Documentation is provided indicating at least one relapse in the last 12 months or two relapses in the last 2 years is provided	
	Therapy is not being used in combination with other biologics for NMOSD (eculizumab, rituximab, satralizumab, tocilizumab, etc.)	
	Individual has an Expanded Disability Status Score (EDSS) score documented at baseline	
Continuation of Therapy (check one)	Yes	No
	Individual continues to meet initial criteria	
	Documentation of positive clinical response with reduction in number and/or severity of relapses or signs and symptoms of NMOSD	
	Documentation is provided indicating recent (within 2 months) EDSS	
PHYSICIAN SIGNATURE – PROVIDER ONLY		
This form <u>must be</u> signed by a provider		
	I certify that the information given in this form is a true and accurate medical indication for the required product	
Name & Title (Printed):		Specialty:
Signature:		